Vitamin B5,Pantothenic Acid / neuroP Cancer Research Results

VitB5, Vitamin B5,Pantothenic Acid: Click to Expand ⟱
Features:
Vitamin B5 (Pantothenic Acid) plays several roles in the brain, and emerging evidence suggests it may be relevant to Alzheimer’s disease (AD)—particularly through its involvement in acetylcholine synthesis, energy metabolism, and oxidative stress response.
-Precursor to Coenzyme A (CoA)
-CoA is essential for mitochondrial energy production, lipid metabolism, and acetylcholine synthesis.
-CoA + choline → acetylcholine. ACh levels are reduced in AD; B5 deficiency may worsen this.
-Pantothenic acid is indirectly involved in cysteamine production, via CoA turnover.
-cysteamine can cross the BBB and increases BDNF levels.
-Pantothenic Acid (D-calcium pantothenate) Most common, stable, and well-absorbed form, water soluable
-Heat(cooking) may degrade the B5.
-Adequate Intake is 5mg/day. Target 10-15mg/day (300–900 mg/day under supervision)

-must be replenished daily; no long-term storage
Beef liver (3 oz cooked)   ~8.3 mg
Sunflower seeds (1 oz)	   ~2.0 mg
Chicken (3 oz cooked)	   ~1.0 mg
Salmon (3 oz cooked)	   ~1.6 mg
Avocado (1 whole)	   ~1.0–2.0 mg
Egg (1 large)	           ~0.7 mg
Mushrooms (½ cup cooked)   ~1.5 mg

Vitamin B5 (Pantothenic Acid; PA) = water-soluble B-vitamin; dietary sources include meats, whole grains, legumes; precursor to Coenzyme A (CoA) and acyl-carrier protein (ACP).
Primary mechanisms (conceptual rank):
1) CoA synthesis → central to acetyl-CoA flux (TCA cycle, fatty acid synthesis/β-oxidation, cholesterol/steroid synthesis).
2) Epigenetic substrate control → acetyl-CoA availability influences histone acetylation (H3/H4 acetyl marks).
3) Redox-metabolic integration → CoA-dependent NADH/FADH2 generation (indirect ROS modulation via mitochondrial flux).
4) Rapidly proliferating cell support → high CoA demand in lipogenic tumors (metabolic permissive role rather than direct cytotoxicity).
PK / bioavailability: efficiently absorbed in small intestine via SMVT transporter; plasma levels tightly regulated; excess rapidly excreted; no meaningful tissue “supra-physiologic” accumulation from oral dosing.
In-vitro vs systemic exposure: most cancer cell studies manipulate CoA enzymes (e.g., PANK) rather than achievable oral PA concentrations; in-vitro millimolar exposures exceed physiological serum levels.
Clinical evidence status: no RCT evidence supporting anti-cancer efficacy; primarily nutritional sufficiency role; deficiency rare.


Vitamin B5 (Pantothenic Acid) — Cancer-Relevant Pathways

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 CoA synthesis / Acetyl-CoA pool ↑ (supports proliferation) ↑ (physiologic support) G Metabolic substrate enabling Central biochemical role; tumors with high lipogenesis depend on robust CoA flux; PA is permissive, not selectively cytotoxic.
2 TCA cycle / mitochondrial flux ↑ (fueling) ↑ R→G Energy metabolism support Indirectly affects NADH/FADH2 production; not a direct ETC inhibitor or activator.
3 Fatty acid synthesis (FASN axis) ↑ (lipogenic tumors) ↑ G Lipid biosynthesis substrate Acetyl-CoA → malonyl-CoA pathway; high relevance in breast, prostate, liver cancers with lipogenic phenotype.
4 Histone acetylation (epigenetic) ↑ (context-dependent) ↑ G Chromatin acetylation permissive Acetyl-CoA availability influences H3/H4 acetyl marks; effect magnitude depends on metabolic state rather than supplementation alone.
5 ROS tone ↔ (indirect) ↔ R Secondary to mitochondrial flux No primary antioxidant property; ROS shifts occur via altered metabolic throughput.
6 NRF2 axis ↔ ↔ G No direct activation Not a canonical NRF2 modulator; any effect is secondary to metabolic stress context.
7 Ca²⁺ signaling ↔ ↔ R No primary modulation No established direct Ca²⁺ regulatory role.
8 Clinical Translation Constraint — — — Nutrient sufficiency only Supplementation does not selectively target tumor metabolism; enzyme-level targeting (e.g., PANK inhibitors) is the investigational strategy.

TSF Legend: P: 0–30 min   |   R: 30 min–3 hr   |   G: >3 hr


Vitamin B5 (Pantothenic Acid; PA) = water-soluble precursor to Coenzyme A (CoA); common supplemental form: D-calcium pantothenate. Present in meats (esp. liver), seeds, fish, eggs, mushrooms; heat-labile to some extent; no long-term storage → requires regular intake.
Primary mechanisms (AD-relevant rank):
1) CoA synthesis → acetyl-CoA pool → acetylcholine (ACh) synthesis support.
2) Mitochondrial energy metabolism (TCA flux, β-oxidation) → neuronal bioenergetic stability.
3) Lipid metabolism (membrane phospholipids, myelin maintenance).
4) Indirect redox integration via mitochondrial throughput (secondary ROS modulation).
5) CoA turnover → cysteamine generation (putative BDNF modulation; limited human data).
PK / exposure: efficiently absorbed; plasma tightly regulated; excess rapidly excreted; oral dosing above AI does not proportionally elevate brain CoA once saturation is reached.
Clinical evidence status (AD): mechanistic plausibility strong; direct RCT evidence lacking; not an established disease-modifying therapy. AD relevance likely greater than cancer (where PA is largely metabolically permissive rather than therapeutic).

Vitamin B5 (Pantothenic Acid) — Alzheimer’s Disease–Relevant Axes

Rank Pathway / Axis Cells (neurons/glia) TSF Primary Effect Notes / Interpretation
1 Acetyl-CoA → Acetylcholine synthesis ↑ (if deficient) G Supports ACh production ACh reduced in AD; PA deficiency could worsen cholinergic deficit; supplementation restores only if suboptimal intake present.
2 Mitochondrial energy metabolism (TCA) ↑ (bioenergetic support) R→G ATP production stabilization CoA central to acetyl-CoA flux; may support neurons under metabolic stress; not a direct ETC activator.
3 Lipid metabolism / membrane integrity ↑ G Phospholipid turnover support Neuronal membrane composition critical in AD; effect is permissive rather than corrective.
4 ROS tone (indirect) ↔ / ↓ (secondary) R Metabolic-redox coupling No intrinsic antioxidant action; ROS shifts occur via improved mitochondrial efficiency (context-dependent).
5 BDNF (via cysteamine from CoA turnover) ↑ (theoretical / limited human data) G Neurotrophic modulation Cysteamine crosses BBB and may increase BDNF; contribution from dietary PA not well quantified clinically.
6 NRF2 axis ↔ G No direct activation Not a canonical NRF2 modulator.
7 Ca²⁺ signaling ↔ R No primary modulation No direct Ca²⁺ regulatory role established.
8 Clinical Translation Constraint — — Nutritional sufficiency ceiling Adequate Intake ~5 mg/day; higher doses (10–15 mg/day typical supplementation; 300–900 mg/day under supervision) lack robust AD outcome trials.

TSF Legend: P: 0–30 min | R: 30 min–3 hr | G: >3 hr
neuroP, neuroprotective: Click to Expand ⟱
Source:
Type:
Neuroprotective refers to the ability of a substance, intervention, or strategy to preserve the structure and function of nerve cells (neurons) against injury or degeneration.
-While cancer and neurodegenerative processes might seem distinct, there is significant overlap in terms of treatment-related neurotoxicity, shared molecular mechanisms, and the potential for therapies that provide neuroprotection during cancer treatment.
Scientific Papers found: Click to Expand⟱
4323- VitB5,    Cerebral deficiency of vitamin B5 (d-pantothenic acid; pantothenate) as a potentially-reversible cause of neurodegeneration and dementia in sporadic Alzheimer's disease
- Study, AD, NA
*Risk↓, *Acetyl-CoA↑, *Ach↑, *neuroP↑,
4326- VitB5,    Cerebral Vitamin B5 (D-Pantothenic Acid) Deficiency as a Potential Cause of Metabolic Perturbation and Neurodegeneration in Huntington’s Disease
- in-vivo, HD, NA
*Risk↓, *neuroP↑, *other?, *Ach↑, *other↝, *eff↓, *other↝,
4329- VitB5,    Long-Term Pantethine Treatment Counteracts Pathologic Gene Dysregulation and Decreases Alzheimer's Disease Pathogenesis in a Transgenic Mouse Model
- in-vivo, AD, NA
*Aβ↓, *Mood↑, *neuroP↑, *Inflam↓, *TNF-α↓, *BBB↝, *other↝, *Dose↝,
4330- VitB5,    Metabolic changes and inflammation in cultured astrocytes from the 5xFAD mouse model of Alzheimer’s disease: Alleviation by pantethine
- in-vivo, AD, NA
*neuroP↑, *Inflam↓, *ATP↑, *G6PD↑, *NADPH↑, *IL1β↓, *other↝,
4334- VitB5,    Pantethine treatment is effective in recovering the disease phenotype induced by ketogenic diet in a pantothenate kinase-associated neurodegeneration mouse model
- in-vivo, AD, NA
*neuroP↑, *motorD↑, *MMP↑, *OCR↑,

Showing Research Papers: 1 to 5 of 5

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 5

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


Mitochondria & Bioenergetics ⓘ

ATP↑, 1,   MMP↑, 1,   OCR↑, 1,  

Core Metabolism/Glycolysis ⓘ

Acetyl-CoA↑, 1,   G6PD↑, 1,   NADPH↑, 1,  

Transcription & Epigenetics ⓘ

Ach↑, 2,   other?, 1,   other↝, 4,  

Barriers & Transport ⓘ

BBB↝, 1,  

Immune & Inflammatory Signaling ⓘ

IL1β↓, 1,   Inflam↓, 2,   TNF-α↓, 1,  

Protein Aggregation ⓘ

Aβ↓, 1,  

Drug Metabolism & Resistance ⓘ

Dose↝, 1,   eff↓, 1,  

Functional Outcomes ⓘ

Mood↑, 1,   motorD↑, 1,   neuroP↑, 5,   Risk↓, 2,  
Total Targets: 20

Scientific Paper Hit Count for: neuroP, neuroprotective
5 Vitamin B5,Pantothenic Acid
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:368  Target#:1105  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page